BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) released its earnings results on Monday. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14), Zacks reports.
BriaCell Therapeutics Trading Up 6.2 %
NASDAQ BCTX opened at $0.65 on Wednesday. BriaCell Therapeutics has a 12 month low of $0.46 and a 12 month high of $5.97. The company’s 50-day moving average price is $0.82 and its 200-day moving average price is $0.86. The stock has a market cap of $23.36 million, a PE ratio of -0.55 and a beta of 1.46.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of BriaCell Therapeutics in a research note on Thursday, December 12th.
About BriaCell Therapeutics
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
Further Reading
- Five stocks we like better than BriaCell Therapeutics
- Which Wall Street Analysts are the Most Accurate?
- Trump’s China Tariffs Could Reshape These 2 Semiconductor Stocks
- How to Read Stock Charts for Beginners
- AppLovin Insiders Sell Shares: Stock Price Indicated Higher
- NYSE Stocks Give Investors a Variety of Quality Options
- Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector Rally
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
